🇺🇸 ABT-348 in United States

1 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 1

Most-reported reactions

1. Acute Kidney Injury — 1 report (100%)

Source database →

Frequently asked questions

Is ABT-348 approved in United States?

ABT-348 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ABT-348 in United States?

AbbVie (prior sponsor, Abbott) is the originator. The local marketing authorisation holder may differ — check the official source linked above.